Search Results
Your search for The ASCO matches 20662 pages
Showing 1301 - 1350Tracking the Progress Being Made in the Treatment of Breast Cancer and the Challenges Ahead
Jame Abraham, MD, FACP, has been in the field of oncology for more than 2 decades, he and says this is both one of the most exhilarating and challenging times in cancer care. “What excites me the most are the innovations in treatment that are literally transforming the lives of our patients and...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Do Patients With Advanced Cancer Value Quality Over Quantity of Life?
A recent study published by Yong et al in Value in Health may help clarify the intricate interplay between the quality-of-life and survival preferences of patients with advanced cancer. Limited access to palliative care services may contribute to suffering, particularly among patients with cancer...
Adjuvant Pembrolizumab May Offer Survival Benefit Over Observation in Patients With Muscle-Invasive or Locally Advanced Urothelial Carcinoma
The Alliance Data and Safety Monitoring Board has determined that adjuvant pembrolizumab may improve disease-free survival in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, according to the Alliance for Clinical Trials in Oncology. ...
KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC
At the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, the benefit of two KRAS G12C inhibitors in advanced non–small cell lung cancer (NSCLC) was upheld by the 2-year follow-up analysis of adagrasib in the KRYSTAL-11 and the early-phase CodeBreaK 101...
Chemotherapy Shortages Ongoing, According to New Survey
The National Comprehensive Cancer Network® (NCCN®) has released a follow-up survey on the ongoing chemotherapy shortages, refreshing findings they originally shared in June 2023. According to their results, 72% of the cancer centers surveyed continue to experience a shortage of carboplatin, and 59% ...
Neighborhood Walkability and Risk of Obesity-Related Cancers
Residing in more walkable neighborhoods could protect against the risk of overall obesity-related cancers in female patients, according to a recent study published by India-Aldana et al in Environmental Health Perspectives. Background Obesity has previously been linked to an increased risk of...
A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life
In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...
Psilocybin
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
National Inventors Hall of Fame Recognizes Jennifer Doudna, PhD; Emmanuelle Charpentier, PhD; and Angela Hartley Brodie, PhD
The National Inventors Hall of Fame (NIHF) recognizes the enduring legacies of exceptional U.S. patent holders on an annual basis. On October 26, 2023, three female inductees will be recognized for their extraordinary contributions to cancer care and clinical research. Biochemist Jennifer...
Circulating Tumor DNA Identified in Breast Milk From Women With Breast Cancer: First Results Published
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum contains circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in...
New Poll Weighs Necessity of Life Expectancy in Cancer Screening Guidelines
A majority of older adults may disagree with the idea of using life expectancy as part of cancer screening guidelines, according to a new University of Michigan National Poll on Healthy Aging. Background The response goes against a trend in guidelines aimed at helping health-care providers decide...
Gilberto de Lima Lopes, Jr, MD, MBA, on Lung Cancer Management: Expert Update
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell,...
Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this...
Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability
Ilias Houda, MD, PhD Candidate, of Amsterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more...
Seshiru Nakazawa, MD, PhD, on NSCLC and Point Mutations as de Novo Oncogenic Drivers
Seshiru Nakazawa, MD, PhD, of Dana-Farber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s...
Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up
Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute, discusses a 5-year follow-up study of patients with metastatic non–small cell lung cancer (NSCLC) who were treated with pembrolizumab plus chemotherapy. According to Dr. Gadgeel, the findings continue to support the use of pembrolizumab...
Diabetes May Be Linked to Lower Survival Among Patients With Multiple Myeloma; Survival Outcomes May Be Race-Dependent
Patients with multiple myeloma who also have diabetes may experience worse overall survival outcomes compared with patients who don’t have diabetes, according to a recent study published by Shah et al in Blood Advances. The new findings demonstrated that the differences in survival may be dependent ...
Liquid Biopsy May Help Identify Patients With NSCLC Who Could Benefit From Radiation Therapy
Liquid biopsy may help determine which patients with oligometastatic non–small cell lung cancer (NSCLC) with metastases may be most likely to benefit from targeted, high-dose radiation therapy rather than drug-based therapy, according to findings simultaneously published by Semenkovich et al in npj ...
Racial and Ethnic Minority Patients With Breast Cancer May Be Less Likely to Receive Palliative Care Than White Patients
Despite a steady increase in palliative care utilization from 2004 to 2020, racial and ethnic minority patients with metastatic breast cancer may be less likely to receive palliative care compared with non-Hispanic White patients with the disease, according to new findings presented by Freeman et...
Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy
Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improving the patient experience, a new study suggests. Patients who may benefit from ...
Sexual Activity and Vaginal Dilation Associated With Fewer Side Effects After Chemoradiation for Cervical Cancer
People who engage in sexual activity or vaginal dilation after chemoradiation for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria. Findings of the EMBRACE study were presented by Kirchheiner et al at the 2023 American Society for...
The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer
Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...
Hypofractionated Radiotherapy May Reduce Burden of Head and Neck Cancer in Low- and Middle-Income Countries
Fewer and higher doses of radiation may be effective at treating patients with head and neck squamous cell carcinoma, according to new findings presented by Bentzen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 02). Background Head and neck squamous...
Liquid Biopsies May Be Predictive of Cancer Recurrence Following Chemoradiation in Patients With Cervical Cancer
Two liquid biopsy tests designed to detect the human papillomavirus (HPV) in the blood may accurately identify patients at high risk of cervical cancer recurrence following the completion of chemoradiation, according to new findings presented by Han et al at the 2023 American Society for Radiation...
Precision Medicine Navigators May Increase Genomic Testing Rates Among Black Patients With Prostate Cancer
The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023...
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation: FABREC Trial
In a first-of-its-kind study, patients with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects, and saved them time and...
Stereotactic Radiotherapy for Patients With Primary RCC Unsuitable for Surgery: FASTRACK II
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests. A multi-institutional phase II study—TransTasman Radiation Oncology Group (TROG) FASTRACK II—found 100% local...
SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B
People with intermediate-risk, localized prostate cancer may be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggested. The findings, which...
Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer
Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the BRIGHTSTAR study, in which brigatinib with local consolidative therapy was found to be safe in patients with ALK-rearranged advanced non–small cell lung cancer. This regimen yielded promising...
FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
On September 29, the U.S. Food and Drug Administration (FDA) granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that may help detect hundreds of genetic variants associated with an elevated risk of developing certain cancers. The...
Chee K. Lee, PhD, MBBS, on Durvalumab, Tremelimumab, and Chemotherapy in NSCLC
Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed durvalumab and tremelimumab with chemotherapy yielded antitumor activity in patients with non–small cell lung cancer (NSCLC) whose tumors progressed after receiving EGFR inhibitors. This...
David H. Harpole, Jr, MD, on Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC
David H. Harpole, Jr, MD, of Duke University Medical Center, discusses further exploratory analyses of patients with EGFR-mutated resectable non–small cell lung cancer (NSCLC) enrolled in the phase III AEGEAN study. In this trial, perioperative durvalumab plus neoadjuvant chemotherapy, vs...
Ticiana A. Leal, MD, on Tumor Treating Fields and Immune Checkpoint Inhibition in Metastatic NSCLC
Ticiana A. Leal, MD, of Winship Cancer Institute at Emory University, discusses phase III findings from the LUNAR study of tumor treating fields (electric fields that disrupt cellular processes and lead to cell death) combined with the standard of care in patients with metastatic non–small cell...
Long-Term Low-Grade Intestinal Inflammation May Be Prevalent Among Patients Who Have Undergone Radiotherapy
Researchers have found that low-grade intestinal inflammation may be a side effect of radiotherapy, according to a recent study published by Devarakonda et al in eBioMedicine. Background Radiotherapy is often necessary to cure cancer or slow down cancer development. Although today’s radiotherapies...
Neoadjuvant Immune Checkpoint Blockade May Be Effective Across Multiple Cancer Types
Neoadjuvant immunotherapy may be effective prior to surgery in multiple types of cancers, according to a recent study published by Topalian et al in Cancer Cell. Background Neoadjuvant immune checkpoint blockades have been a rapidly growing area of research and are currently being tested across...
Tom E. Stinchcombe, MD, on NSCLC: Strategies for Managing Secondary Primary Disease
Tom E. Stinchcombe, MD, of Duke Cancer Institute, discusses an analysis of the rate of second primary lung cancer from the CALGB (Alliance) 140503 trial of lobar vs sublobar resection for T1a N0 non–small cell lung cancer (NSCLC). The data have implications for surveillance and screening strategies ...
Desheng Liang, MD, PhD, on Genetic Engineering of Mesenchymal Stem Cells for Cancer Therapy
Desheng Liang, MD, PhD, of China’s Central South University, discusses the ability of mesenchymal stem cells to target tumor and the progress he and his team have made in genetically engineering these cells for cancer treatment. Mesenchymal cells, which hold promise for therapeutic advances, are...
Unconscious Gender Biases and Discrimination Lead to Suboptimal Care for Women
Gender inequalities and discrimination may adversely impact women’s rights and opportunities to avoid cancer risk factors and impede their ability to seek and obtain timely diagnoses and quality cancer care, according to The Lancet Commission on Women, Power, and Cancer published by Ginsburg et al...
Using Whole-Body Imaging Agent to Predict Response to Treatment in HER2-Positive Metastatic Breast Cancer
The novel imaging agent gallium (Ga)-68–ABY-025 may help to predict early metabolic response to HER2-targeted treatment in patients with HER2-positive metastatic breast cancer, according to a recent study published by Alhuseinalkhudhur et al in The Journal of Nuclear Medicine. These findings...
Hyperglycemia Among Patients With Breast Cancer Receiving Alpelisib
Researchers have uncovered elevated rates of hyperglycemia among patients who have breast cancer receiving treatment with alpelisib, according to a recent study published by Shen et al in Cancer. Background Alpelisib is designed to target the phosphoinositide 3-kinase (PI3K) protein, which is...
Mutations in 11 Genes May Be Associated With Aggressive Prostate Cancer
Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...
Bariatric Surgery May Reduce the Risk of Hematologic Malignancies, Particularly Among Female Patients
The risk of developing hematologic malignancies may decrease following bariatric surgery in patients with overweight or obesity, according to a recent study published by Sjöholm et al in The Lancet Healthy Longevity. Background Previous studies have shown that overweight and obesity may be risk...
FDA Approves Bosutinib for Pediatric Patients With Chronic Myelogenous Leukemia
On September 26, the U.S. Food and Drug Administration (FDA) approved bosutinib (Bosulif) for pediatric patients aged 1 year and older with chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. The FDA ...
Gynecologic Cancer Misinformation May Be Widespread on TikTok
The majority of information related to gynecologic cancers on the social media platform TikTok may be misleading or inaccurate, according to a recent study published by Morton et al in Gynecologic Oncology. Background “The intent of this study was to understand the needs of patients that may go...
Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma
Investigators have revealed that oral health may be associated with survival in patients with head and neck squamous cell carcinoma, according to a novel study published by Tasoulas et al in the Journal of the National Cancer Institute. Background While survival has improved during the past decades ...
High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome
Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....
Exposure to PFAS and Phenols May Be Linked to Cancer Risk
Investigators have discovered that significantly higher levels of endocrine-disrupting chemicals such as per- and poly-fluoroalkyl substances (PFAS) and phenols may be present in patients with breast, ovarian, skin, and endometrial cancers, according to a recent study published by Cathey et al in...
MD Anderson and Ochsner Health Partner to Create First Fully Integrated Cancer Program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans–based Ochsner Health recently announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Patients with cancer in the region now will have access to treatments that are among the most advanced in...
